£11.5M
ARCH Venture Partners led the oversubscribed round alongside participation from +ND Capital, OMX Ventures, and Meltwind.
Syndex Bio
Syndex Bio advances next-generation molecular diagnostics with its proprietary methyl-copying PCR platform.
£11.5MTotal raised
Syndex Bio is a biotechnology company developing proprietary molecular technologies to detect epigenetic alterations with unprecedented precision. The firm has introduced its methyl-copying PCR platform to improve molecular diagnostics.
Filed accounts
Cash at bank
Members only
Net current assets
Members only
Total assets less current liabilities
Members only
Net assets
Members only
Shareholders' funds
Members only
Fixed assets
Members only
Cash, assets and headcount from Syndex Bio's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
GS
Geoff Smith
Founder and CEO
Geoff is the founder and CEO of Syndex Bio. He previously served as managing director at CompendiumBio Limited and held advisory roles across several companies.
LinkedIn